Aprea Therapeutics
Aprea developed eprenetapopt, a drug meant to restore the function of mutant p53, which failed its phase 3 trial in TP53-mutant myelodysplastic syndromes in 2020; the company now works on ATR and WEE1 inhibitors.
Overview
Aprea Therapeutics, founded in Stockholm and now based in Doylestown, Pennsylvania and listed on Nasdaq, developed eprenetapopt (APR-246), a small molecule intended to refold mutant p53 into its active form. Combined with azacitidine it produced encouraging phase 2 remissions in TP53-mutant myelodysplastic syndromes, but the phase 3 trial missed its complete remission endpoint in December 2020. The company pivoted to DNA damage response drugs, including the ATR inhibitor ATRN-119 and a WEE1 inhibitor. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Scorecard
All companies- targets +2
- modalities +2
- registry trials +7
- failures -3
Similar pages
not linked directly; found by shared links- CompanyOrca Biosystems
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyTreadwell Therapeutics
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyRyvu Therapeutics
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyEllipses Pharma
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyShenzhen TargetRx
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag ctgov-sponsor.
- Companyargenx
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyOncoVerity
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyMolecular Partners
Shares Acute myeloid leukaemia and the tag ctgov-sponsor.